Shire and NanoMedSyn to collaborate on enzyme replacement therapies

Rare disease specialist Shire (LSE: SHP) has entered into a collaboration with Montpellier, France-based NanoMedSyn, a biotech company focused on enzyme replacement therapies (ERT).

The firms will work together on preclinical research to evaluate a potential ERT using NanoMedSyn’s proprietary synthetic derivatives, called AMFA.

Shire chief scientific officer Andreas Busch said: “The novel design of AMFA and the promising biological activity demonstrated in preclinical models makes this program an exciting opportunity for Shire to further expand its commitment to evaluating potential advancements in lysosomal storage disorder treatments.”